Lilly’s JAK2 inhibitor from $2.3bn acquisition shows early promise
Eli Lilly’s type II JAK2 inhibitor, which it acquired through the $2.3bn acquisition of Ajax Therapeutics earlier this year, has…
Latest News
-
-
Takeda’s oral TYK2 blocker outperforms Sotyktu in PsA trial
Takeda’s oral tyrosine kinase 2 (TYK2) inhibitor has outperformed Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque…
-
Clinical trials vital for UK to access innovative medicines, expert says
UK patients cannot expect to access approved innovative medicines if the country does not adequately contribute to clinical trials, an…
-
Novartis $12bn bet on Avidity well placed after mid-stage FSHD win
Novartis’ $12bn Avidity Biosciences buyout is looking increasingly well positioned, as one of the latter company’s lead assets, delpacibart braxlosiran…
-
Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials
Gilead Sciences and MSD’s human immunodeficiency virus (HIV) once weekly tablet combination has met primary endpoints in two Phase III…
-
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA
AstraZeneca has unveiled data from two Phase IIb trials of its in-licensed oral glucagon-like peptide-1 receptor agonist (GLP-1RA), touting a…
-
ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly
The past weekend has seen a number of major data presentations at the American Diabetes Association (ADA) conference 2026. While…
-
ADA26: key obesity readouts from the conference
As the 2026 American Diabetes Association (ADA) conference draws to a close for another year, Clinical Trials Arena gives you…
-
Argenx’s Vyvgart shows durability in myositis and Sjögren’s
Argenx’s Vyvgart (efgartigimod alfa-fcab) shows lengthy benefit for myositis and Sjögren’s disease, setting up its anticipated Phase III readouts. The…
-
EMA and AMA collaborate on Ebola trials amid public health emergency
The European Medicines Agency’s (EMA’s) emergency task force (ETF) is engaging with the African Medicines Agency (AMA) to plan clinical…
